Does Aetna Cover Jardiance?

Aetna Formulary Placement for Jardiance in 2025 to 2026

Aetna includes Jardiance on the majority of its commercial and Medicare Advantage formularies, though the specific tier varies by plan. On most Aetna commercial plans, empagliflozin sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). This distinction matters because Tier 2 drugs carry lower copays, typically $25 to $50, while Tier 3 drugs may cost $60 to $90 per fill [1].

Aetna's formulary decisions draw on clinical evidence and cost-effectiveness reviews. The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease (HR 0.62 to 95% CI 0.49, 0.77) [2]. These results, along with ADA Standards of Care recommendations positioning SGLT2 inhibitors as preferred second-line therapy for patients with atherosclerotic cardiovascular disease or heart failure, have strengthened Jardiance's formulary standing across most major insurers [3].

Your exact tier depends on which Aetna plan you carry. An Aetna Open Choice PPO may list Jardiance differently than an Aetna Innovation Health HMO. The only way to confirm your specific tier is to check your plan's formulary through Aetna's online member portal or call the number on the back of your insurance card.

Prior Authorization Requirements

Aetna requires prior authorization for Jardiance on nearly all plan types. This means your prescribing physician must submit clinical documentation before Aetna approves coverage. The process is standard but adds a step between the prescription and the pharmacy counter.

According to Aetna's published clinical policy bulletins, prior authorization for empagliflozin generally requires documentation of a confirmed type 2 diabetes diagnosis (per ADA diagnostic criteria), current HbA1c, and evidence of metformin use or a documented contraindication to metformin [4]. For heart failure indications, documentation of left ventricular ejection fraction and NYHA functional class is typically requested, consistent with 2022 AHA/ACC/HFSA heart failure guidelines [5].

The approval process usually takes 24 to 72 hours for standard requests. Urgent requests, submitted when a delay could cause serious harm, receive a decision within 24 hours. If denied, your physician can file a peer-to-peer review or a formal appeal. About 50% to 60% of initial prior authorization denials for brand-name diabetes drugs are overturned on appeal when supported by appropriate clinical documentation, according to data from the American Medical Association's 2024 prior authorization survey [6].

Step Therapy: What Aetna Requires Before Approving Jardiance

Step therapy is Aetna's protocol for requiring patients to try a lower-cost medication before the insurer covers a higher-cost drug. For Jardiance, Aetna commonly requires a trial of metformin (typically 90 days at maximum tolerated dose) before approving SGLT2 inhibitor coverage [4].

This requirement applies to the type 2 diabetes indication specifically. Patients prescribed Jardiance for heart failure with reduced ejection fraction (based on the EMPEROR-Reduced trial, N=3,730, where empagliflozin reduced the combined risk of cardiovascular death or heart failure hospitalization by 25% vs. placebo) [7] or for chronic kidney disease (based on the EMPA-KIDNEY trial, N=6,609) [8] may qualify for step therapy exceptions, since metformin is not the standard of care for those conditions.

Your doctor can request a step therapy exception if metformin is contraindicated. Common accepted reasons include an eGFR below 30 mL/min/1.73m², documented gastrointestinal intolerance despite extended-release formulation trials, lactic acidosis risk factors, or a history of adverse reaction to metformin. The exception request goes through the same prior authorization channel and typically adds no more than one to two business days to the review timeline.

What Jardiance Costs with Aetna Insurance

Out-of-pocket costs for Jardiance under Aetna depend on your plan's benefit design, tier placement, and whether you have met your deductible. Here is a general breakdown by plan type.

Aetna Commercial Plans (Employer-Sponsored)

Most Aetna employer plans use a copay structure for brand drugs. If Jardiance is on Tier 2, expect $25 to $50 per 30-day supply. If it falls on Tier 3, the range is $60 to $90. Some high-deductible health plans (HDHPs) paired with HSAs require you to pay the full negotiated price until meeting your deductible, which could mean $300 to $500 per fill before deductible satisfaction [1].

Aetna Medicare Advantage (Part D)

Under Aetna Medicare Advantage plans, Jardiance is generally covered during the initial coverage phase with copays of $47 to $100 depending on tier and plan. Once you enter the coverage gap (the "donut hole"), the Inflation Reduction Act caps insulin costs at $35 per month, but this cap does not apply to SGLT2 inhibitors like Jardiance. However, the IRA's $2,000 annual out-of-pocket maximum for Part D, effective since 2025, does limit total yearly drug spending [9]. Patients reaching that cap pay $0 for the rest of the calendar year.

Aetna Medicaid Managed Care

Coverage varies by state. Some state Medicaid formularies managed by Aetna Better Health include Jardiance; others restrict it to patients who have failed multiple generic alternatives. Check your state's Medicaid preferred drug list for the definitive answer.

How to Lower Your Jardiance Copay with Aetna

Even with Aetna coverage, Jardiance is expensive compared to generic diabetes medications. Several strategies can reduce your out-of-pocket cost.

Boehringer Ingelheim Copay Card. The manufacturer offers a savings card that can reduce out-of-pocket costs to as low as $10 per month for commercially insured patients. This card is not valid for patients with government insurance, including Medicare, Medicaid, Tricare, or VA coverage. The savings card covers up to $300 per 30-day prescription, and annual maximum benefit limits apply [10].

Boehringer Ingelheim Patient Assistance Program. Uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level ($62,400 for an individual in 2025) may qualify for free Jardiance through the manufacturer's patient assistance program [10].

Aetna's Preferred Alternatives. If cost is prohibitive, ask your physician whether switching to a formulary-preferred SGLT2 inhibitor might work. On some Aetna plans, Farxiga (dapagliflozin) or Invokana (canagliflozin) may sit on a lower tier with a lower copay. All three SGLT2 inhibitors share the same class-level cardiovascular and renal benefits recognized by the ADA, though head-to-head trial data remain limited [3].

90-Day Mail Order. Aetna's CVS Caremark mail-order pharmacy often provides a 90-day supply for the cost of two copays instead of three, saving roughly 33% per fill cycle. Check your plan documents or call Aetna to confirm mail-order eligibility for Jardiance.

Jardiance for Heart Failure and CKD: Does Aetna Cover Non-Diabetes Uses?

Jardiance received FDA approval for heart failure with reduced ejection fraction (HFrEF) in 2022 and for chronic kidney disease in 2023 [11]. These expanded indications changed the coverage picture.

Aetna covers Jardiance for heart failure and CKD on most plans, but prior authorization criteria differ from the type 2 diabetes indication. For heart failure, Aetna typically requires documentation of LVEF at or below 40%, NYHA Class II, IV symptoms, and current use of guideline-directed medical therapy including an ACE inhibitor/ARB/ARNI and a beta-blocker, unless contraindicated [5].

The EMPEROR-Preserved trial (N=5,988) extended the evidence for empagliflozin to heart failure with preserved ejection fraction (HFpEF), showing a 21% relative reduction in the combined risk of cardiovascular death or heart failure hospitalization [12]. Coverage for HFpEF (LVEF above 40%) is still inconsistent across Aetna plans, with some requiring additional clinical justification.

For chronic kidney disease, the EMPA-KIDNEY trial showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64, 0.82, P<0.001) across patients with and without diabetes [8]. Aetna plans that have updated their coverage criteria to reflect the 2024 KDIGO guidelines generally cover Jardiance for CKD with albuminuria and eGFR between 20 and 45 mL/min/1.73m² [13].

How to Check Your Specific Aetna Coverage

Confirming your coverage takes about 10 minutes. Three methods work.

Online Member Portal. Log in to Aetna.com, manage to "Find a Medication," and search for empagliflozin or Jardiance. The result shows your plan's tier, copay estimate, prior authorization requirements, and step therapy status.

Call Member Services. The number is on the back of your Aetna card. Ask specifically: "Is Jardiance on my formulary, what tier is it, and does it require prior authorization or step therapy?" Write down the reference number for the call.

Ask Your Pharmacist. Your pharmacist can run a real-time benefit check through your Aetna prescription plan. This generates an actual copay estimate at the point of sale and will flag prior authorization requirements before you leave the counter. Real-time benefit tools have been shown to reduce prescription abandonment by 10% to 15% in commercially insured populations, per a 2023 analysis in the American Journal of Managed Care [14].

Jardiance vs. Generic SGLT2 Options Under Aetna

No generic version of empagliflozin is currently available in the United States. Jardiance's core patents are expected to provide market exclusivity through at least 2028. This means cost comparisons focus on other branded SGLT2 inhibitors rather than generic equivalents [11].

Aetna may prefer one SGLT2 inhibitor over another based on negotiated rebates, not clinical superiority. The 2024 ADA Standards of Care treat empagliflozin, dapagliflozin, and canagliflozin as clinically interchangeable for cardiovascular and renal benefit in type 2 diabetes [3]. The practical question is which one your specific Aetna plan places on the lowest tier.

If your physician has a clinical reason for preferring Jardiance specifically (for example, the EMPA-REG OUTCOME data showing the 38% cardiovascular mortality reduction, which was larger than the non-significant 13% reduction seen with canagliflozin in CANVAS) [2][15], that rationale can support a coverage exception request. Aetna's exception process requires a letter of medical necessity from your prescriber documenting why the preferred alternative is inappropriate for your case.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "SGLT2 inhibitors have become a pillar of type 2 diabetes management, particularly for patients with coexisting cardiovascular or kidney disease. Insurance access to these medications should reflect the strength of their clinical evidence" [3].

The Endocrine Society's 2023 clinical practice guideline on pharmacologic treatment of type 2 diabetes similarly notes: "Given the cardiovascular and renal benefits demonstrated across the SGLT2 inhibitor class, access barriers such as step therapy and prior authorization should be minimized for eligible patients" [16].

What to Do If Aetna Denies Jardiance Coverage

A denial is not the end. There are structured appeal pathways.

First, request the denial letter in writing. Aetna is required to provide the clinical rationale for the denial, including the specific policy criteria you did not meet. Review this with your physician to determine whether additional documentation can address the gap.

Second, file a formal appeal within 60 days of the denial. Your physician should include updated lab work (HbA1c, eGFR, urine albumin-to-creatinine ratio), a summary of failed prior therapies, and a letter of medical necessity citing relevant trial data. The EMPA-REG OUTCOME, EMPEROR-Reduced, and EMPA-KIDNEY trials provide strong evidence for cardiovascular, heart failure, and renal indications respectively [2][7][8].

Third, if the internal appeal fails, you have the right to an external review by an independent review organization (IRO). The IRO's decision is binding on Aetna. For Medicare Advantage denials, the process goes through the Part D coverage determination and appeals pathway, with escalation to the Medicare Appeals Council if needed [9].

The entire process from initial denial to IRO decision typically takes 30 to 60 days. During this period, ask your physician about bridge samples or the manufacturer's copay assistance program to maintain medication continuity.